GSK and J&J spend billions to boost their cancer drug pipelines
Monday, December 3, 2018 - 14:40
in Health & Medicine
GSK will acquire Tesaro for its PARP inhibitor niraparib as J&J partners with Argenx to develop a drug for blood cancers